Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 9;11(6):372. doi: 10.3390/metabo11060372

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Changes in renal fatty acid metabolism by pemafibrate in experiment two. (A) Serum and renal free fatty acid levels. (B) Renal adenosine triphosphate content. (C) Renal expressions of mRNA related to fatty acid metabolism. (D) Renal protein levels related to fatty acid metabolism. Significant differences compared with the FAON group are indicated with # (p < 0.05). Abbreviations: FFA, free fatty acid; ATP, adenosine triphosphate; Ppara (PPARα), peroxisome proliferator activated receptor alpha; TBP, TATA-binding protein; Cpt2 (CPT2), carnitine palmitoyl-transferase 2; Acadvl (VLCAD), very long-chain acyl-CoA dehydrogenase; Acadm (MCAD), medium-chain acyl-CoA dehydrogenase; Hadha (TPα), mitochondrial trifunctional protein α subunits; Acox1 (ACOX), acyl-CoA oxidase; Ehhadh (PH), L-peroxisomal bifunctional protein; Acaa1 (PT), peroxisomal 3-ketoacyl-CoA thiolase; CON, control; FAON, fatty acid overload nephropathy; PEM, pemafibrate.